Physician profile
William Sumner
NPI 1871579110
$3,854.24
in general payments reported to CMS, 2019-2025
23 companies · $1,605 in 2025
The $1,605 reported for 2025 was more than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $35.16 · 2021: $99.80 · 2022: $264 · 2023: $415 · 2024: $1,140 · 2025: $1,605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,000 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,999.65 |
| Education | $161.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $815.95 | 2019-2025 | Humira, Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $550.51 | 2019-2025 | Tremfya |
| Genzyme Corporation | $361.84 | 2019-2025 | |
| Lilly USA, LLC | $353.08 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $263.33 | 2019-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $184.31 | 2023-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $181.86 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $146.78 | 2020-2025 | Ilumya |
| Leo Pharma INC. | $139.31 | 2022-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $134.09 | 2023-2025 | Sotyktu |
| Amgen INC. | $108.70 | 2019-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $105.97 | 2019-2025 | |
| Dermavant Sciences, INC. | $81.27 | 2023-2024 | Vtama |
| Pfizer INC. | $67.09 | 2023-2025 | |
| Almirall LLC | $62.76 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $61.94 | 2019 | |
| Botanix Sb INC | $57.59 | 2025 | Sofdra |
| Galderma Laboratories, L.P. | $51.40 | 2024-2025 | Nemluvio |
| Journey Medical Corporation | $38.12 | 2022-2025 | |
| Regeneron Pharmaceuticals, INC. | $36.99 | 2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.76 | 2025 | Spevigo |
| Sandoz INC. | $16.07 | 2025 | Hyrimoz |
| Organon LLC | $14.52 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Sumner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.